Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease

Study summary

This clinical trial evaluates the feasibility and effectiveness of a post-transplant dental cleaning for the prevention of chronic graft versus host disease (GVHD) in patients undergoing an allogeneic hematopoietic cell transplant (HCT). HCT is the only curative treatment for some types of blood cancer. Unfortunately, this approach can lead to the development of GVHD, which is a disease caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Some research has shown that the bacteria that is present in the dental plaque soon after transplant may affect the development of chronic GVHD. Dental cleanings prior to transplant are part of the normal standard of care for patients undergoing HCT. Adding an additional cleaning shortly after HCT may be effective for preventing the development of chronic GVHD.

Ask AI to explain this study

Start here

Key things to know

Main goalPrevention

This describes the study’s primary purpose.

What is being studiedDental Cleaning and Dental Plaque sampling

The study team can explain what participation involves.

Who it may be forChronic Graft Versus Host Disease · Acute Graft Versus Host Disease

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Oct 21, 2026 · Source: ClinicalTrials.gov

Is enrollment open?Recruiting

The study is currently accepting participants.

What kind of study?Not applicable

Interventional

Where is it offered?1 U.S. location

Locations may change over time.

Who runs it?Fred Hutchinson Cancer Center

Study sponsor

Study overview

What this study is about

Purpose: Prevention
Study type: Interventional
Phase: Not applicable
Sponsor: Fred Hutchinson Cancer Center
Interventions being studied: Procedure: Dental Cleaning; Procedure: Dental Plaque sampling

Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria

Age ≥ 18 years old
T-replete allogeneic hematopoietic cell transplantation for any indication. History of prior transplantation is allowed. Any conditioning regimen is allowed
One of the following HCT donor types:
9/10 or 10/10 human leukocyte antigen (HLA)-matched unrelated donor
Cord blood
Willing to have an in-person 1-year long-term follow-up (LTFU) visit including an oral medicine at Fred Hutch (FH)
Ability to understand and sign a written informed consent document (or legal representative)

Reasons someone may not be able to joinExclusion criteria

Edentulous state
Bone marrow as graft source
Use of post-transplantation cyclophosphamide (PTCy) or ruxolitinib as GVHD prophylaxis
Use of anti-thymocyte globulin (ATG) in conditioning

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

Study sites

U.S. locations

Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Oct 21, 2026. Always confirm current availability with the study team.

View original record ↗